Cargando…

Exploring protective effect of Glycine tabacina aqueous extract against nephrotic syndrome by network pharmacology and experimental verification

BACKGROUND: Glycine tabacina (Labill.) Benth, one of the traditional Chinese herbal medicines, has been used for treatment of nephritis, osteoporosis, rheumatism, and menopausal syndrome. The aim of this study was to illuminate the therapeutic effect and mechanism of Glycine tabacina aqueous extract...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Lihua, Tu, Yanbei, Wang, Kai, Han, Bing, Peng, Hongquan, He, Chengwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395350/
https://www.ncbi.nlm.nih.gov/pubmed/32765640
http://dx.doi.org/10.1186/s13020-020-00361-7
_version_ 1783565389320421376
author Tan, Lihua
Tu, Yanbei
Wang, Kai
Han, Bing
Peng, Hongquan
He, Chengwei
author_facet Tan, Lihua
Tu, Yanbei
Wang, Kai
Han, Bing
Peng, Hongquan
He, Chengwei
author_sort Tan, Lihua
collection PubMed
description BACKGROUND: Glycine tabacina (Labill.) Benth, one of the traditional Chinese herbal medicines, has been used for treatment of nephritis, osteoporosis, rheumatism, and menopausal syndrome. The aim of this study was to illuminate the therapeutic effect and mechanism of Glycine tabacina aqueous extract (GATE) in the treatment of nephrotic syndrome (NS). METHODS: UHPLC-DAD-MS/MS was used to analyze the chemical profile of GATE. Adriamycin (ADR)-induced NS mouse model and network pharmacology methods were conducted to explore the protective effect and mechanism of GATE on NS treatment. RESULTS: GATE administration significantly ameliorated symptoms of proteinuria and hyperlipidemia in NS mice, as evidenced by reduced excretion of urine protein and albumin, and decreased plasma levels of total cholesterol and triglyceride. Decreased blood urea nitrogen (BUN) and creatinine levels in NS mice suggested that GATE could prevent renal function decline caused by ADR. GATE treatment also inhibited ADR-induced pathological lesions of renal tissues as indicated by periodic acid Schiff staining. Six flavonoids of GATE were identified by using UHPLC-DAD-MS/MS. Network pharmacology analysis indicated that the protection of GATE in treating NS might be associated with the regulation of oxidative stress and inflammation. In addition, the in vivo experiment validated that treatment with GATE markedly decreased reactive oxygen species production, malonaldehyde level, and increased superoxide dismutase activity both in plasma and renal tissues. TNF-α level in plasma and protein expression in kidney were significantly decreased in GATE treatment groups. CONCLUSIONS: Combination of network pharmacology analysis and experimental verification revealed that GATE exerts anti-NS effect possibly through modulating oxidative stress and inflammation, suggesting the potential application of GATE or its derivatives in the prevention and treatment of NS and other related kidney diseases.
format Online
Article
Text
id pubmed-7395350
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73953502020-08-05 Exploring protective effect of Glycine tabacina aqueous extract against nephrotic syndrome by network pharmacology and experimental verification Tan, Lihua Tu, Yanbei Wang, Kai Han, Bing Peng, Hongquan He, Chengwei Chin Med Research BACKGROUND: Glycine tabacina (Labill.) Benth, one of the traditional Chinese herbal medicines, has been used for treatment of nephritis, osteoporosis, rheumatism, and menopausal syndrome. The aim of this study was to illuminate the therapeutic effect and mechanism of Glycine tabacina aqueous extract (GATE) in the treatment of nephrotic syndrome (NS). METHODS: UHPLC-DAD-MS/MS was used to analyze the chemical profile of GATE. Adriamycin (ADR)-induced NS mouse model and network pharmacology methods were conducted to explore the protective effect and mechanism of GATE on NS treatment. RESULTS: GATE administration significantly ameliorated symptoms of proteinuria and hyperlipidemia in NS mice, as evidenced by reduced excretion of urine protein and albumin, and decreased plasma levels of total cholesterol and triglyceride. Decreased blood urea nitrogen (BUN) and creatinine levels in NS mice suggested that GATE could prevent renal function decline caused by ADR. GATE treatment also inhibited ADR-induced pathological lesions of renal tissues as indicated by periodic acid Schiff staining. Six flavonoids of GATE were identified by using UHPLC-DAD-MS/MS. Network pharmacology analysis indicated that the protection of GATE in treating NS might be associated with the regulation of oxidative stress and inflammation. In addition, the in vivo experiment validated that treatment with GATE markedly decreased reactive oxygen species production, malonaldehyde level, and increased superoxide dismutase activity both in plasma and renal tissues. TNF-α level in plasma and protein expression in kidney were significantly decreased in GATE treatment groups. CONCLUSIONS: Combination of network pharmacology analysis and experimental verification revealed that GATE exerts anti-NS effect possibly through modulating oxidative stress and inflammation, suggesting the potential application of GATE or its derivatives in the prevention and treatment of NS and other related kidney diseases. BioMed Central 2020-08-01 /pmc/articles/PMC7395350/ /pubmed/32765640 http://dx.doi.org/10.1186/s13020-020-00361-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Tan, Lihua
Tu, Yanbei
Wang, Kai
Han, Bing
Peng, Hongquan
He, Chengwei
Exploring protective effect of Glycine tabacina aqueous extract against nephrotic syndrome by network pharmacology and experimental verification
title Exploring protective effect of Glycine tabacina aqueous extract against nephrotic syndrome by network pharmacology and experimental verification
title_full Exploring protective effect of Glycine tabacina aqueous extract against nephrotic syndrome by network pharmacology and experimental verification
title_fullStr Exploring protective effect of Glycine tabacina aqueous extract against nephrotic syndrome by network pharmacology and experimental verification
title_full_unstemmed Exploring protective effect of Glycine tabacina aqueous extract against nephrotic syndrome by network pharmacology and experimental verification
title_short Exploring protective effect of Glycine tabacina aqueous extract against nephrotic syndrome by network pharmacology and experimental verification
title_sort exploring protective effect of glycine tabacina aqueous extract against nephrotic syndrome by network pharmacology and experimental verification
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395350/
https://www.ncbi.nlm.nih.gov/pubmed/32765640
http://dx.doi.org/10.1186/s13020-020-00361-7
work_keys_str_mv AT tanlihua exploringprotectiveeffectofglycinetabacinaaqueousextractagainstnephroticsyndromebynetworkpharmacologyandexperimentalverification
AT tuyanbei exploringprotectiveeffectofglycinetabacinaaqueousextractagainstnephroticsyndromebynetworkpharmacologyandexperimentalverification
AT wangkai exploringprotectiveeffectofglycinetabacinaaqueousextractagainstnephroticsyndromebynetworkpharmacologyandexperimentalverification
AT hanbing exploringprotectiveeffectofglycinetabacinaaqueousextractagainstnephroticsyndromebynetworkpharmacologyandexperimentalverification
AT penghongquan exploringprotectiveeffectofglycinetabacinaaqueousextractagainstnephroticsyndromebynetworkpharmacologyandexperimentalverification
AT hechengwei exploringprotectiveeffectofglycinetabacinaaqueousextractagainstnephroticsyndromebynetworkpharmacologyandexperimentalverification